Document:

Exhibit 10.7

 Exhibit 10.7 
 

 
 September 17, 2014 

Ms. Bernice Kuca 
 [Home Address Redacted] 

Dear Bernice: 
 It is with great pleasure that I extend to you a
conditional offer of employment to join CoLucid Pharmaceuticals, Inc. as Vice President, Clinical and Regulatory Operations. As Vice President, Clinical and Regulatory Operations, you will be responsible for all aspects of design and execution of
clinical trials as well as all aspects of regulatory interactions with both the Food and Drug Administration and foreign equivalents. 
 As you know,
CoLucid is working toward the closing of its Series C financing, anticipated to be completed on or before January 13, 2015. Assuming we meet this target closing date, your employment will become effective on January 13, 2015. If for some
reason the closing is delayed, your employment will become effective the day after closing, except that in the unlikely event that the Series C financing does not close by January 30, 2015, this letter and the conditional offer of employment
herein will be automatically withdrawn and terminated as of February 1, 2015. On the date your employment becomes effective, your Consulting Agreement with CoLucid, dated July 18, 2011 (including all Project Statements thereunder), will be
terminated and superseded in its entirety by the provisions of this employment letter and the enclosed Confidentiality, Inventions and Non-Competition Agreement, which we ask you to sign and return with this letter. Pending the effectiveness of your
employment, the Consulting Agreement will remain in full force and effect unless and until it is terminated in accordance with its terms. By signing below, you will be signifying your agreement to these provisions. 

As compensation for your employment, you will receive a starting salary of $225,000.00 on an annualized basis. You may also be eligible for incentive
compensation up to 20% of your base salary based upon Company and individual performance. You are also a participant in the Company’s Employee and Consultant Transaction Incentive Plan dated August 9, 2012 which is appended to this letter,
in lieu of equity or incentive stock option incentives. Of course, your participation in the Transaction Incentive Plan is subject to all of the terms and conditions of the Plan, including the Board’s right to terminate your participation in
the Plan or to terminate the Plan in its entirety. You also will be eligible to participate in CoLucid’s employee benefit plans, subject to the eligibility requirements and other terms and conditions of such plans. Such employee benefit plans,
which are subject to change from time to time, will be provided to you as they become available (the Company will be evaluating its current plans for revision during the month of September). In addition, during your initial year of employment, you
will receive three weeks of paid time off (this includes all vacation days, sick days, personal days, etc.) to be used in accordance with CoLucid’s paid time off policy. 

 It is our understanding that you do not have any contractual obligations (such as a non-competition or non-solicitation agreement) with a former or current employer. If our understanding is incorrect, please notify us immediately. If you have a confidentiality obligation with a former or current
employer, it is your responsibility to refrain from using or disclosing any protected confidential information during the course of your employment with CoLucid. If you have any questions about this responsibility, please let me know. 

Although we hope your employment with CoLucid will be long and mutually beneficial, this letter is not a contract of employment or guarantee of employment for
any specific duration. Your employment with CoLucid will be on an at-will basis, which means either you or CoLucid may terminate the employment relationship at any time for any reason. 

If this offer is acceptable, please indicate your acceptance by signing and dating this letter where indicated below and returning the signed original to me,
along with the enclosed Confidentiality, Inventions and Non-Competition Agreement, by September 30, 2014. A duplicate copy of this letter is enclosed for your file. 

We are excited to have you join the CoLucid team. We are confident that you will make a valuable contribution to our growing organization and will find
working here challenging and rewarding. Should you have any questions, please do not hesitate to contact me. 
 Sincerely, 

 

	
	/s/ Thomas P. Mathers
	
	Thomas P. Mathers
	Chief Executive Officer

 ACCEPTED: 
  

			
	 /s/ Bernice Kuca

	Bernice Kuca
		
	Date:		 25 September 2014Exhibit 10.8

 Exhibit 10.8 

CoLucid Pharmaceuticals, Inc. 

March 14, 2006 
 Dr. Nadia Rupniak 

[Home Address Redacted] 
 Dear Dr. Rupniak: 

On behalf of CoLucid Pharmaceuticals, Inc. (the “Company”), I am delighted to offer you the position of Executive Director of Project and Alliance
Management. Your employment will begin effective as of March 14, 2006 (the “Effective Date”). Some of the main responsibilities related to this position are referenced in the attached position description. As you know, job duties may
be modified as needed. You will report directly to the Chief Executive Officer of the Company. 
 Compensation and Benefits 

Your starting salary will be $160,000 per year, payable in accordance with the Company’s regular payroll practices. Your net compensation will be less all
applicable deductions, withholding taxes and other amounts required by federal and state laws. 
 Performance bonuses will be awarded in accordance with
policies established from time to time by the Board of Directors of the Company. 
 You will be granted options to purchase 100,000 shares of the
Company’s Common Stock. The options will be governed in all respects by the Company’s 2006 Equity Incentive Plan. The options will be incentive stock options. The option grant will be subject to your execution and delivery of an
option agreement in form and substance acceptable to the Company. The option agreement will provide for a four-year vesting period as follows: One-fourth (1/4) of
your options will vest and become exercisable on February 20, 2007, and the remaining three-fourths (3/4) of the options will vest and become exercisable in equal monthly installments on the last day
of each month, beginning March 31, 2007, over the following 36 months. 
 As an important member of the CoLucid team, you will be eligible to
participate in the employee group benefit plans described in the CoLucid Employee Handbook, subject to any eligibility requirements of such benefit plans. The handbook initially includes a vacation policy, health care policy and 401(k) plan,
but the handbook and benefits are subject to change from time to time. 
 At-Will Employment 

Your employment with the Company is “at will” and is subject to the terms of this letter. While this offer letter states the initial terms of your
employment, it is not an employment agreement and does not create an obligation by either you or the Company to continue the employment relationship for any specific period of time. These initial employment terms may be changed in the future. 

As you are aware, your employment by the Company is a full-time position. You will be required to devote your full
time, attention, skill and effort to the operations of the Company and you will not engage, with or without compensation, in any other business activity; provided, however, that you will be permitted to devote an average of eight hours per
month for the first 12 months of your employment to consulting for Dynogen Pharmaceuticals, Inc., and you will be permitted to continue reviewing 

  

					
	Dr. Nadia Rupniak		 -
 2
 -		March 14, 2006

  

 manuscripts for scientific journals and publications, in each case so long as such consulting and manuscript
review do not adversely impact your service to the Company or violate any provision of the Supplemental Agreement referred to below. 
 You hereby represent
and warrant to the Company that you are not subject to any employment, non-competition or other similar agreement or restriction that would prevent or interfere with the Company’s employment of you on the
terms set forth herein. 
 In the event that your employment is terminated by the Company without cause, then, upon your furnishing to the Company an
effective release of all claims in a form acceptable to the Company, (a) the Company shall compensate you (in a lump sum) for any accrued, unused vacation time as of the termination date and continue to pay your then effective salary (less
standard deductions and withholdings) in accordance with the Company’s regular payroll practices for a period ending upon the earlier of (i) three months following the termination date or (ii) the date as of which you commence self-employment or employment with another company or business entity, and (b) any Company options held by you that would have vested during the 90-day period immediately following the termination date shall
accelerate and become vested as of the termination date. For purposes of this paragraph, (x) your employment will be considered to have been terminated by the Company without cause if the Company requires, as a condition of your continued
employment, that you relocate more than 50 miles from Research Triangle Park, North Carolina, and if, due to such requirement, you choose to resign your employment with the Company, and (y) your consulting work with Dynogen
Pharmaceuticals, Inc., referred to above shall not be deemed to constitute self-employment for purposes of clause (a)(ii) above. 

Should your employment with the Company terminate for any reason, you agree to submit to an exit interview for the purposes of reviewing this offer letter and
the Supplemental Agreement. 
 Supplemental Agreement and I-9 Forms 

Your employment is conditioned upon your execution of a Confidentiality, Inventions and Non-Competition Agreement (the
“Supplemental Agreement”). A copy of the Supplemental Agreement is enclosed. 
 The Company is required by law to obtain evidence of your legal
right to work in the United States within three days of your date of hire. Please provide this evidence at your earliest convenience. 
 We
believe your skills and commitment will be valuable assets to the Company and we are confident that you will find your new position both challenging and rewarding. Please confirm your acceptance of this offer by signing and returning a copy of this
letter and the Supplemental Agreement. 
 We look forward to having you join the team at CoLucid. Should you have any questions regarding the provisions of
employment, please do not hesitate to ask. 
  

			
	Sincerely,
	
	COLUCID PHARMACEUTICALS, INC.
	
	 /s/ J. F. White

	James White, President and CEO

					
	Dr. Nadia Rupniak		 -
 3
 -		March 14, 2006

  

			
	Accepted and agreed:
	
	 /s/ Nadia Rupniak

	Nadia Rupniak

 Description of Responsibilities for 

Executive Director of Project and Alliance Management 

The Executive Director of Program and Alliance Management will be responsible for leading and coordinating all scientific activities associated with CoLucid
programs. The initial program is focused on the development of a 5HT1f agonist for migraine. The person in this position will lead a multi-disciplinary team to advance this program through Phase II clinical trials, development of an optimized
dosage form and advance the program through longer term preclinical safety studies. In addition, this person will lead efforts to advance the Sention stigmine program over time to the Phase I stage.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]